^
Association details:
| Biomarker: | PMS2 mutation |
|---|---|
| Cancer: | Melanoma |
| Drug Class: | Immunotherapy |
| Direction: | Sensitive |
Evidence:
Source:
Title:
769P - Analysis of PMS2 mutation as a potential biomarker for melanoma immunotherapy
Published date:
09/05/2022
Excerpt:
Multivariable analysis of validation cohort demonstrated that PMS2 mutation was associated with better OS (HR= 0.10; 95%CI, 0.01-0.71; P = 0.021), after adjusting for age, gender, metastasis type, ICI type….Analysis of discovery and validation cohort data shows PMS2 mutation is associated with better OS in ICI-treated patients. These findings indicates that PMS2 mutation may serve as a potential predictive biomarker for ICIs in melanoma.
